## LS9 Closes $25M Round; Chevron Takes a Stake ##### 24 September 2009  LS9 modifies the ACP pathway in bacteria to produce renewable hydrocarbon fuels and chemicals with optimized properties. Source: LS9. Click to enlarge. LS9 Company, a synthetic biology company producing renewable fuels and chemicals directly by fermentation, has successfully completed a$25 million round of funding. Participating investors included CTTV Investments LLC, the venture capital arm of Chevron Technology Ventures LLC; Flagship Ventures; Khosla Ventures and Lightspeed Venture Partners.

LS9 has engineered a one-step process using to convert fatty acid intermediates into petroleum replacement products via fermentation of renewable sugars. LS9 has also discovered and engineered a new class of enzymes and their associated genes to efficiently convert fatty acids into hydrocarbons.

LS9 is currently producing UltraClean Diesel at its pilot facility. UltraClean Diesel has achieved US and Brazilian performance standards for on-road use, and achieves an 85% reduction in green house gas emissions. (Earlier post.) In addition, LS9 UltraClean Diesel contains no carcinogens, such as benzene, and only trace amounts of sulfur.

LS9’s technology also makes it possible to create superior products that can achieve optimal overall performance. LS9 has demonstrated its ability to modify the genetic makeup of its microorganisms and precisely tailor LS9 end-products to have improved fuel properties such as cetane, volatility, oxidative stability and cold-flow. LS9 will have demonstration scale production of UltraClean Diesel in 2010.

In addition to low-carbon transportation fuels, LS9’s one-step fermentation process is capable of producing chemicals used in making industrial and consumer products. LS9 previously announced a partnership with Procter & Gamble to jointly develop and commercialize LS9 technology for use in the production of key consumer chemicals within the Procter & Gamble portfolio. (Earlier post.)

LS9 modifies the membrane lipids biosynthesis pathway in bacteria using synthetic operons to produce the hydrocarbon products. The biochemistry of that ACP pathway is well understood and controllable, said Steve del Cardayre, LS9 Vice President, Research and Development, in a synthetic biology webinar earlier this year. Precise product composition and performance is engineered genetically for specific end-use.

With advances in the tools of molecular biology, he noted then, system design is becoming the limiting factor to such synthetic biology solutions as opposed to system construction.

Resources

"..Chevron Takes a Stake" has no details. They 'took stake' in EV NiMH batteries too.

The traditional oil companies should not be allowed to have any connection or ownership of renewable or alternative fuel companies. Massive investments of oil money into good alternative fuels research could eliminate any desires of the inventors to bring the products to market. The comments about batteries is the obvious other side of the coin, the direct blocking of the use of technology.

The recent National Geographic has a story about Redwood trees that states that only five percent of the natural forests are left. This should cause some thought about the continued development of biofuels.

The absolute CO2 and other green house gas release during the production of foreign oils cannot be determined and can be easily far higher than a local coal to liquids conversion unit if methane is released at all, so no coal to liquid conversions should be blocked by any comments or concerns about CO2 release. Much CO2 release of such units can be compensated for by the co-production of electricity and heat. Remember, every human breathes out CO2.

..HG..

This is not as big as the \$600 million investment by Exxon, but could get this company going forward.

I have no problem with oil companies investing in bio fuels companies. I would like them to leave room for other investors and not corner the market however.

The comments to this entry are closed.